Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 44%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences is a Buy with a promising outlook driven by its well-rounded portfolio of transcatheter and surgical heart valve products, including the successful TAVR business which has stabilized and has potential for re-acceleration with the asymptomatic rollout and possible NCD update. The company's upcoming product launches in mitral and tricuspid therapies and its focus on margin expansion also support a positive long-term growth trajectory. Other potential catalysts, such as the final TAVR NCD and new product approvals, add to the company's potential for success in the dynamic macroeconomic environment. With a solid growth profile, competitive moat, and best-in-class product pipeline, Edwards Lifesciences is well-suited to outperform in the cardiovascular device market.

Bears say

Edwards Lifesciences is an established leader in the medical device industry, with a strong focus on advanced stages of structural heart disease. While the company has recently outperformed its peers, its current premium valuation may not be sustainable given potential market saturation and competitive pressures. The company's large percentage of international sales also exposes it to currency and geopolitical risks. Additionally, increased investments and expenses related to its field salesforce and patient access initiatives may weigh on profitability in the short term.

Edwards Lifesciences (EW) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 44% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 18 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.